ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)

Its studies are mostly in Neoplasm Metastasis, led by Beijing Biotech.

Furthest: phase 2, since Mar 14, 20262 company-led studies, 2 open or runningNext primary completion: Feb 14, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Biotech22 open or runningphase 2since Mar 14, 2026Mar 14, 2026Feb 14, 2027phase 2 · NCT07480928

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 14, 2026First study: phase 2 study in Neoplasm MetastasisFirst studyNCT07480928 · 42 planned · China
  2. May 31, 2026Phase 2 study in Neoplasm MetastasisNCT07627711 · 42 planned · China

Ahead

  1. Feb 14, 2027Primary completion: phase 2 study in Neoplasm MetastasisNCT07480928
  2. Apr 14, 2027Primary completion: phase 2 study in Neoplasm MetastasisNCT07627711

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07627711Neoplasm Metastasis · China2RecruitingApr 14, 202742
NCT07480928Neoplasm Metastasis · China2RecruitingFeb 14, 202742

How it is read

Names in the registry

  • “EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.